AR122983A1 - ANTICUERPOS ANTI-a4b7 - Google Patents
ANTICUERPOS ANTI-a4b7Info
- Publication number
- AR122983A1 AR122983A1 ARP210101993A ARP210101993A AR122983A1 AR 122983 A1 AR122983 A1 AR 122983A1 AR P210101993 A ARP210101993 A AR P210101993A AR P210101993 A ARP210101993 A AR P210101993A AR 122983 A1 AR122983 A1 AR 122983A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr
- seq
- antibodies
- cdrs
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción proporciona anticuerpos anti-a4b7 que se unen a a4b7 humanas, sus métodos de fabricación y sus usos para tratar pacientes con infección por VIH. Reivindicación 1: Un anticuerpo anti-a4b7 humana el cual comprende (i) una cadena VH que comprende tres CDR y (ii) una cadena VL que comprende tres CDR, en donde: VH CDR#1 es GFNIKNTYMH (SEQ ID Nº 72); VH CDR#2 es RIDPAKGHTEYAPKFLG (SEQ ID Nº 73); VH CDR#3 es VDV (SEQ ID Nº 74); VL CDR#1 es HASQDISDNIG (SEQ ID Nº 75); VL CDR#2 es HGTNLED (SEQ ID Nº 76) y VL CDR#3 es VQYAQFPWT (SEQ ID Nº 77).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052933P | 2020-07-16 | 2020-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122983A1 true AR122983A1 (es) | 2022-10-19 |
Family
ID=77338969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101993A AR122983A1 (es) | 2020-07-16 | 2021-07-15 | ANTICUERPOS ANTI-a4b7 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11639390B2 (es) |
| EP (1) | EP4182349A1 (es) |
| JP (2) | JP7408008B2 (es) |
| KR (1) | KR20230038728A (es) |
| CN (1) | CN115867352A (es) |
| AR (1) | AR122983A1 (es) |
| AU (1) | AU2021307468A1 (es) |
| BR (1) | BR112023000718A2 (es) |
| CA (1) | CA3188739A1 (es) |
| CO (1) | CO2023001066A2 (es) |
| IL (1) | IL299767A (es) |
| MX (1) | MX2023000732A (es) |
| TW (1) | TW202216781A (es) |
| UY (1) | UY39327A (es) |
| WO (1) | WO2022016198A1 (es) |
| ZA (1) | ZA202300222B (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AP2015008338A0 (en) * | 2012-09-26 | 2015-04-30 | Kflp Biotech Llc | Compounds for the treatment and prevention of retroviral infections |
| WO2018104893A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
-
2021
- 2021-07-15 UY UY0001039327A patent/UY39327A/es unknown
- 2021-07-15 AR ARP210101993A patent/AR122983A1/es unknown
- 2021-07-16 WO PCT/US2021/070898 patent/WO2022016198A1/en active Application Filing
- 2021-07-16 IL IL299767A patent/IL299767A/en unknown
- 2021-07-16 KR KR1020237004136A patent/KR20230038728A/ko unknown
- 2021-07-16 AU AU2021307468A patent/AU2021307468A1/en active Pending
- 2021-07-16 CN CN202180049613.2A patent/CN115867352A/zh active Pending
- 2021-07-16 TW TW110126301A patent/TW202216781A/zh unknown
- 2021-07-16 EP EP21755330.4A patent/EP4182349A1/en active Pending
- 2021-07-16 MX MX2023000732A patent/MX2023000732A/es unknown
- 2021-07-16 JP JP2023502654A patent/JP7408008B2/ja active Active
- 2021-07-16 US US17/378,565 patent/US11639390B2/en active Active
- 2021-07-16 CA CA3188739A patent/CA3188739A1/en active Pending
- 2021-07-16 BR BR112023000718A patent/BR112023000718A2/pt unknown
-
2023
- 2023-01-04 ZA ZA2023/00222A patent/ZA202300222B/en unknown
- 2023-01-31 CO CONC2023/0001066A patent/CO2023001066A2/es unknown
- 2023-12-18 JP JP2023212722A patent/JP2024037932A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535556A (ja) | 2023-08-18 |
| UY39327A (es) | 2022-02-25 |
| MX2023000732A (es) | 2023-02-13 |
| CA3188739A1 (en) | 2022-01-20 |
| AU2021307468A1 (en) | 2023-02-02 |
| EP4182349A1 (en) | 2023-05-24 |
| BR112023000718A2 (pt) | 2023-02-07 |
| TW202216781A (zh) | 2022-05-01 |
| CN115867352A (zh) | 2023-03-28 |
| JP2024037932A (ja) | 2024-03-19 |
| US20220017624A1 (en) | 2022-01-20 |
| IL299767A (en) | 2023-03-01 |
| US11639390B2 (en) | 2023-05-02 |
| WO2022016198A1 (en) | 2022-01-20 |
| JP7408008B2 (ja) | 2024-01-04 |
| CO2023001066A2 (es) | 2023-02-06 |
| KR20230038728A (ko) | 2023-03-21 |
| ZA202300222B (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20161431A1 (es) | Anticuerpos biespecificos que se unen a cd38 y cd3 | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| CO2018002265A2 (es) | Anticuerpos anti-cd19 humano humanizados | |
| PE20081478A1 (es) | Anticuerpos cd44 | |
| CL2021001628A1 (es) | Anticuerpo humanizado anti-pd-1 humana | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| AR085600A1 (es) | Agentes de union biespecifica | |
| AR082194A1 (es) | Anticuerpos anti-ron | |
| AR094960A1 (es) | Anticuerpos de quimiocina pan-elr⁺ cxc | |
| ECSP22097203A (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso | |
| CO2022018426A2 (es) | Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso | |
| AR122983A1 (es) | ANTICUERPOS ANTI-a4b7 | |
| CL2022003755A1 (es) | Muteínas de il-10 y proteínas de fusión de las mismas |